title: Hormonal treatment before radical prostatectomy: a 3-year followup.
abstract: OBJECTIVE
  Hormonal treatment administered before radical prostatectomy has been shown to decrease the rate of positive surgical margins. We determine whether preoperative hormonal treatment has any impact on the subsequent failure rate.
  
  
  METHODS
  We prospectively evaluated 122 patients with stages T1bNxM0 to T3aNxM0, grades 1 to 3 prostate cancer, including 64 randomly assigned to immediate radical retropubic prostatectomy and 58 randomly assigned to radical retropubic prostatectomy preceded by 3 months of pretreatment with a gonadotropin-releasing hormone agonist. We performed intention to treat analysis on the data with failure defined as lymph node involvement, serum prostate specific antigen greater than 0.5 ng./ml., or the need for postoperative hormonal or radiation adjuvant treatment.
  
  
  RESULTS
  The positive margin rate was 23.6 versus 45.5% in the pretreatment plus prostatectomy versus prostatectomy only groups (p = 0.016). There were 20 failures (34.5%) in the pretreatment plus prostatectomy subgroup and 26 (40.6%) in the prostatectomy only group (p = 0.48). A negative surgical margin was associated with a significantly lower risk of progression than a positive surgical margin (20.8 versus 50.0%, p = 0.0016), and progression was delayed by approximately 1 year after hormonal pretreatment. However, at a median followup of 38 months there was no difference in progression-free survival (p = 0.57).
  
  
  CONCLUSIONS
  Although hormonal pretreatment significantly decreased the positive margin rate, it did not result in any difference in progression-free survival when followup exceeded 3 years. Thus, our current results do not support the routine administration of hormonal treatment before radical prostatectomy.
authors.affiliation: Department of Urology, Göteborg University, Sweden.
authors.forename: G
authors.initials: G
authors.lastname: Aus
authors.forename: P A
authors.initials: PA
authors.lastname: Abrahamsson
authors.forename: G
authors.initials: G
authors.lastname: Ahlgren
authors.forename: J
authors.initials: J
authors.lastname: Hugosson
authors.forename: S
authors.initials: S
authors.lastname: Lundberg
authors.forename: M
authors.initials: M
authors.lastname: Schain
authors.forename: S
authors.initials: S
authors.lastname: Schelin
authors.forename: K
authors.initials: K
authors.lastname: Pedersen
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D011300:Preoperative Care; D011446:Prospective Studies; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D017211:Treatment Failure; D017329:Triptorelin Pamoate / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017329:Triptorelin Pamoate